American Pain Society 2011

Tanezumab, a monoclonal antibody that inhibits nerve growth factor, is efficacious in treating osteoarthritis pain and may provide greater symptomatic improvement compared with placebo and naproxen, according to results presented at the American Pain Society’s 30th Annual Scientific Meeting.

Data presented at the American Pain Society’s 30th Annual Scientific Meeting demonstrated that NGX-4010, a capsaicin 8% patch significantly reduces pain in older patients with postherpetic neuralgia (PHN), a debilitating condition characterized by persistent pain following the healing of a herpes zoster rash.

Perioperative use of etoricoxib, a selective COX-2 inhibitor, in patients undergoing total abdominal hysterectomy significantly reduces both resting and elicited pain and opioid (morphine) consumption compared with placebo, according to results presented at the American Pain Society’s 30th Annual Scientific Meeting.

A subgroup analysis presented at the American Pain Society’s 30th Annual Scientific Meeting demonstrated that fentanyl buccal soluble film is effective in the management of breakthrough neuropathic pain in cancer patients.

Monthly Prescribing Reference (MPR) is proud to deliver extensive news coverage of the 30th American Pain Society Annual Scientific Meeting live, in May, from Austin, Texas. For 3 days during the conference, MPR‘s team of reporters will post informative articles from sessions and abstract and poster presentations. Coverage will focus on evolving therapies and the…